Navigation Links
Quest Diagnostics Reports First Quarter 2013 Financial Results
Date:4/17/2013

e first quarter was adversely impacted by a number of factors, our efforts to restore growth, which are building momentum, coupled with easier year-over-year comparisons for the remainder of the year and the expectation of additional acquisitions, give us confidence in our full year outlook for 2013," Mr. Rusckowski said.

For 2013, the company estimates results from continuing operations, before special items, as follows:

  • Revenues now expected to approximate the prior year level, compared to previous guidance of 0% to 1% growth;
  • Earnings per diluted share to be between $4.35 and $4.55, unchanged;
  • Cash provided by operations to approximate $1 billion, unchanged; and
  • Capital expenditures to approximate $250 million, unchanged
  • Note on Non-GAAP Financial MeasuresAs used in this press release, the term "adjusted" refers to the operating performance measures that exclude restructuring and integration charges and CEO succession costs. Adjusted measures are presented because management believes those measures are useful adjuncts to reported results under accounting principles generally accepted in the United States. Adjusted measures should not be considered as an alternative to the corresponding measures determined under accounting principles generally accepted in the United States.

    Conference Call InformationQuest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests participants dial in approximately 10 minutes before the call. A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 800-835-4373 for domestic callers, or 402-280-1657 for international callers. Telephone replays will be available from 10:30 a.m. Eastern Time o
    '/>"/>

    SOURCE Quest Diagnostics Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
    2. Software Pioneer Leaves $10 Million Bequest To Five Leading Non-profits In Health And Drug Policy Reform
    3. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
    4. Quest Diagnostics to Release Second Quarter 2012 Financial Results on July 19
    5. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
    6. Questcor to Report Second Quarter Results on July 24, 2012
    7. Watson and Actavis Receive FTC Second Request
    8. Questcor Reports Second Quarter Financial Results
    9. Roper Industries to Acquire Sunquest Information Systems
    10. Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
    11. Quest Diagnostics Launches Molecular Cervical Cancer Test Based on National Institutes of Healths TERC Gene Marker
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... 17, 2014 Research and Markets ... Cancer Market 2014-2018" report to their offering. ... growth of cancerous cells in the breast tissue. It ... cancer is rare. Histologically, breast cancer can be classified ... undifferentiated carcinoma. Ductal carcinoma is the form of breast ...
    (Date:9/16/2014)... , 17. September 2014 ... ), hat heute die Markteinführung des ... Probenverarbeitung, in Europa bekannt gegeben. Der ... Universalplattform zur Vereinfachung der präanalytischen Probenverarbeitung. ... und fehlerbehaftete Arbeitsschritte bei der manuellen ...
    (Date:9/16/2014)... 2014 3SBio Inc., ("3SBio") a leading ... focusing on researching, developing, manufacturing and marketing ... into an exclusive license agreement with JenKem Technology ... marketing in Mainland China of PEG-irinotecan, a long-acting ... is over-expressed in many solid tumors, including colorectal, ...
    Breaking Medicine Technology:Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 2Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 3Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5
    ... N.J., Oct. 27 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., filed a new drug application under Section ... (FFDCA) with the U.S. Food and Drug Administration (FDA) ... and 40 mg tablets.  Watson,s rosuvastatin zinc tablets are ...
    ... Oct. 27 Intrinsic Bioprobes today announced that ... issued US Patent 7,816,095 covering novel blood protein ... first of a series of patent applications that ... clinical utility. "The biomarkers were discovered ...
    Cached Medicine Technology:Watson Confirms Crestor® Patent Challenge 2Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction 2
    (Date:9/17/2014)... Acceleratio Ltd., an innovative software development ... of Server Monitoring Toolkit , a web ... It brings real-time server monitoring via a live ... enhanced features that significantly improve troubleshooting and detection ... agentless data collection, a user-friendly interface, and many ...
    (Date:9/17/2014)... 17, 2014 Lintelus, Inc., a ... it has released Lintelus Meeting Version 3.1, designed ... corporate events. The newest release includes features to ... management capabilities and allow a more personalized event ... Lintelus Meeting 3.1 offers product advancements including real-time ...
    (Date:9/17/2014)... HERNDON, VIRGINIA (PRWEB) September 17, 2014 ... top rhinoplasty specialist surgeons, has been recognized as a recipient ... is reserved for only the best of the best as ... by specialty. , Dr. Naderi, who is affectionately known by ... of only a handful of true rhinoplasty specialist ...
    (Date:9/17/2014)... Promising new research published in the ... on the potential ability of ketones to support brain ... The study shows that brain hypometabolism associated ... impaired glucose uptake and/or utilization, and results suggest that ... The study, by the Research Center on Aging and ...
    (Date:9/17/2014)... TENN. September 16, 2014) A study led ... found the chemotherapy dose threshold below which male ... sperm production. The study appears in September 17 ... , By clarifying which patients are at highest ... expect the findings to eventually increase use of ...
    Breaking Medicine News(10 mins):Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 3Health News:Lintelus Energizes Audiences with the Latest Version Of its Multi-Screen Interactive Software 2Health News:Vitals Honors Dr. Shervin Naderi With Top 10 Doctor Award 2Health News:Vitals Honors Dr. Shervin Naderi With Top 10 Doctor Award 3Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 3Health News:Improved risk identification will aid fertility preservation in young male cancer patients 2Health News:Improved risk identification will aid fertility preservation in young male cancer patients 3
    ... , , WEDNESDAY, Nov. 14 (HealthDay News) -- During a ... drugs to be sold by pharmacists without a prescription, ... for and against the proposal by representatives of various ... day,s end, the FDA officials said they weren,t ready ...
    ... a,statement from Jeff Levi, Executive Director of Trust ... (TFAH) urges Congress to override the,President,s veto of ... Agencies Appropriations bill., The Labor/HHS bill provides ... states, territories, localities and hospitals to prepare for,public ...
    ... Kalamazoo, Mich.-based,Stryker Corporation and its former outpatient ... pay the United States $16.6,million to settle ... and other federal health care programs, the ... allegations that Physiotherapy, which is based,in Memphis, ...
    ... announced today,that the U.S. Food and Drug ... beta) for the treatment of anemia,associated with ... patients,on dialysis and patients not on dialysis. ... (CKD). MIRCERA is the only FDA-approved,erythropoiesis-stimulating agent ...
    ... Conference Call Scheduled for November 20, NAPA, Calif., ... specialty life sciences company engaged in the,study of senescense, ... skincare,and dermatological therapeutics today announced financial results for the,quarter ... quarter 2007 were $469,000 compared to,$2,027,000 for the same ...
    ... Natural Nutrition,(OTC Bulletin Board: NNTN) ( http://www.naturalnutritioninc.com ) ... of 10-QSB. Chris Mathers, CFO of,Natural Nutrition said, ... filing for Natural Nutrition will not be filed ... record revenue of $12.644,million and record EBITDA of ...
    Cached Medicine News:Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Stryker Corp. & Physiotherapy Associates to Pay U.S. $16.6 Million for Alleged False Claims to Federal Health Care Programs 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 3Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 2Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 3Health News:Natural Nutrition to Report Record Revenue and EBITDA in Late Filing of 10-QSB 2
    ... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
    ... Aspen® CTO combines highly effective immobilization of ... a level of comfort that makes it ... substantially progressive immobilization in going from a ... and then on to a four-post orthosis. ...
    ... Shoulder Immobilizer with Contoured ... Navy cotton sling with foam-padded ... body straps. Quick-release closure buckles. ... 35 covered abduction wedge to ...
    The Humeral Stabilizing System is a terrific option for immobilization of stable humeral fractures, stablesupracondular fractures, and biceps/triceps repairs....
    Medicine Products: